Aprea Therapeutics, Inc. — Q3 2023 Form 10-Q
Reporting period: Three and nine months ended September 30, 2023; filed November 9, 2023. Aprea is a clinical-stage oncology company with no approved products or product sales. Its lead candidate, ATRN-119, is in early clinical development.
Financial results and liquidity
| Metric | Q3 2023 | Q3 2022 | Nine months 2023 | Nine months 2022 |
|---|---|---|---|---|
| Grant revenue | $0.32 million | None | $0.57 million | None |
| Research and development | $2.12 million | $1.12 million | $5.58 million | $15.87 million |
| General and administrative | $1.72 million | $3.08 million | $6.78 million | $18.85 million |
| Net loss | $3.20 million | $4.02 million | $10.84 million | $110.22 million |
| Net loss per share | $0.86 | $2.32 | $3.03 | $83.33 |
- Cash and cash equivalents were $25.35 million at September 30, 2023, down from $28.79 million at December 31, 2022. Restricted cash was $0.04 million.
- Operating cash use for the first nine months was $8.44 million; investing cash use was $0.09 million; financing provided $5.14 million. Ending cash, cash equivalents and restricted cash totaled $25.39 million.
- Current assets were $25.64 million and current liabilities $4.17 million. The balance sheet reports no debt. Accumulated deficit was $304.64 million.
- The company reported no product-sales revenue; grant revenue came from a National Cancer Institute grant. Product margins are not applicable at this stage.
Changes versus comparable periods
- Q3 net loss narrowed by $0.82 million year over year. R&D rose by $1.01 million, primarily due to ATRN-1051 IND-enabling work; G&A fell by $1.36 million, reflecting lower professional fees, insurance premiums and personnel costs.
- Nine-month net loss declined sharply from 2022, mainly because 2022 included a $76.02 million acquired in-process R&D charge for the Atrin acquisition. Lower 2023 R&D and G&A also reflected reduced legacy eprenetapopt activity and substantially lower stock-based compensation, including accelerated vesting in 2022.
- Spending on ATRN-119 and ATRN-1051 increased as their development progressed. A February 2023 public offering raised approximately $4.9 million net; ATM sales added approximately $0.3 million net. Common shares outstanding increased from 2.66 million at year-end 2022 to 3.74 million at September 30, 2023.
Outlook, risks and unusual items
- Management said September 30 cash was expected to fund operations and capital requirements through the end of Q4 2024. This estimate depends on assumptions that may prove inaccurate. The company expects to need additional financing; without it, it may reduce, delay or curtail development.
- The company expected ATRN-119 Phase 1 tolerability and pharmacokinetic data in Q1 2024. The first three dose cohorts were complete, with enrollment continuing in additional cohorts. It anticipated filing an IND for WEE1 inhibitor ATRN-1051 by the end of 2023. These were forward-looking expectations, not reported outcomes.
- Principal risks include early-stage clinical uncertainty, patient enrollment and regulatory delays, dependence on third parties—including a single manufacturer for API and drug product—and limited financing capacity. The filing also cites macroeconomic and financial-market risks.
- The filing states that all cash, cash equivalents, restricted cash and available-for-sale investments were held with Silicon Valley Bank; the September 30 balance sheet lists cash and restricted cash but no available-for-sale investments. Verify the cash custody and concentration disclosures.
- No material legal proceedings or contingent-loss provision were reported. The company disclosed no off-balance-sheet arrangements. Its 2020 shelf registration statement was set to expire November 30, 2023, and ATM capacity was constrained by the Form S-3 public-float limitation.
Key investor verification points
- Confirm cash balances, bank custody and concentration, and whether the stated Q4 2024 runway remains achievable under updated spending and financing assumptions.
- Check subsequent ATRN-119 clinical data and the timing and status of the ATRN-1051 IND filing.
- Assess remaining financing options, shelf/ATM availability, potential dilution and the effect of the public-float limitation.
- Distinguish recurring development spending from prior-period acquisition and accelerated stock-compensation charges when comparing losses.
- Review subsequent filings for clinical, manufacturing, regulatory, Nasdaq-listing and other material risk developments.